Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Nivolumab demonstrated superior efficacy in LA-HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung …
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline …
1 天前 · The first-line combination of nivolumab (Opdivo) and chemotherapy continued to show deep responses and an overall survival (OS) benefit vs chemotherapy alone in patients with …
Evorpacept Plus TRP Betters Survival in HER2+ Gastric/GEJ Cancer
1 天前 · The CD47 myeloid checkpoint inhibitor evorpacept (ALX148), in combination with trastuzumab (Herceptin), paclitaxel, and ramucirumab (Cyramza; TRP), resulted in favorable …
Daratumumab With Lenalidomide Enhances Outcomes in NDMM
2 天之前 · Ashraf Z. Badros, MB, ChB, professor of medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology at the …
Patient Considerations for Front-line Systemic Immunotherapies in …
1 天前 · James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for …
Breast Cancer | Oncology News & Insights | Targeted Oncology
January 13th 2025. During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of …
ADCs Change the Game for Cancer Treatment - Targeted Oncology
2024年5月29日 · Loncastuximab Tesirine. The CD19-directed loncastuximab tesirine-lpyl (Zynlonta) gained an FDA orphan drug designation in 2017 7 and was granted accelerated …
Treatment Resources - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
GI CANCERS - Targeted Oncology
January 17th 2025. LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for pancreatic cancer treatment.
Prostate Cancer - Targeted Oncology
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment …